Home

Novavax, Inc. (NVAX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Novavax, Inc. (NVAX)

Go deeper and ask any question about NVAX

Company Performance

Current Price

as of Sep 13, 2024

$13.61

P/E Ratio

N/A

Market Cap

$2.18B

Description

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Metrics

Overview

  • HQGaithersburg, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerNVAX
  • Price$13.61+14.18%

Trading Information

  • Market Cap$2.18B
  • Float95.58%
  • Average Daily Volume (1m)5,546,147
  • Average Daily Volume (3m)7,232,457
  • EPS-$2.67

Company

  • Revenue$987.67M
  • Rev Growth (1yr)-2.11%
  • Net Income$162.38M
  • Gross Margin91.33%
  • EBITDA Margin41.70%
  • EBITDA$173.25M
  • EV$1.27B
  • EV/Revenue1.29
  • P/EN/A
  • P/S2.29
Documents
SEC Filings
8-K (2024-08-08)
8-K (2024-06-14)
8-K (2024-06-06)
8-K (2024-05-23)
8-K (2024-05-13)
8-K (2024-05-10)
8-K (2024-04-26)
8-K (2024-03-26)
8-K (2024-02-28)
8-K (2024-02-22)
8-K (2024-01-31)
8-K (2024-01-08)
8-K (2023-12-05)
8-K (2023-11-17)
8-K (2023-11-09)
8-K (2023-10-03)
8-K (2023-08-08)
8-K (2023-07-11)
8-K (2023-07-07)
8-K (2023-05-09)
8-K (2023-04-04)
8-K (2023-03-22)
8-K (2023-03-14)
8-K (2023-03-02)
8-K (2023-02-28)
8-K (2023-01-09)
10-Q (2024-08-08)
10-Q (2024-05-10)
10-Q (2023-11-09)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2024-02-28)
10-K (2023-02-28)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Novavax, Inc. Q3 ($6.83, +0.03) (2023-11-09T18:42:09Z)
Novavax's updated protein-based COVID-19 vaccine now an option for all 194 member states of the WHO ($5.46, 0.00) (2023-11-28T11:03:23Z)
Novavax's COVID-19 vaccine Nuvaxovid receives full approval in Singapore ($6.45, 0.00) (2023-10-18T12:04:34Z)
Novavax, Inc. reports Q3 GAAP EPS ($1.26) vs year-ago ($2.15) - 10-Q ($6.80, 0.00) (2023-11-09T12:37:11Z)
Novavax, Inc. issues press release on Q3 results; reports Q3 GAAP EPS ($1.26) vs FactSet ($1.80) [6 est, ($2.71)-0.28]; prepares to initiate cost reduction program ($6.80, 0.00) (2023-11-09T14:07:35Z)
Novavax receives full marketing authorization for prototype COVID-19 vaccine Nuvaxovid ▼ in United Kingdom ($6.45, 0.00) (2023-10-18T12:08:16Z)
Novavax finalizes agreements with pharmacy retailers and GPOs to provide the company's Covid-19 vaccine ($7.45, 0.00) (2023-10-13T13:33:32Z)
Novavax comments on WHO's recommendation of R21/Matrix-M malaria vaccine ($7.17, -0.07) (2023-10-02T17:07:59Z)
Novavax appoints John Trizzino to newly created role of President and COO ($5.83, 0.00) (2023-11-17T12:17:26Z)
Follow-up: FDA amends EUA for Novavax's COVID-19 vaccine to include 2023-2024 formula ($6.84, -0.25) (2023-10-03T18:44:13Z)
CORRECTION: Novavax, Inc. guides FY revenue $900M-$1.10B vs prior guidance $1.30-1.50B and FactSet $1.37B [6 est, $1.35-1.40B] ($6.80, 0.00) (2023-11-09T14:11:02Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-09)
Earnings Report (2023-08-08)
Factset
Factset Business Description
Wikipedia
Novavax,_Inc.